npj Vaccines
(Nov 2021)
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
Mayuresh M. Abhyankar,
Barbara J. Mann,
Jeffrey M. Sturek,
Savannah Brovero,
G. Brett Moreau,
Anjali Sengar,
Crystal M. Richardson,
Sayeh Agah,
Anna Pomés,
Peter M. Kasson,
Mark A. Tomai,
Christopher B. Fox,
William A. Petri
Affiliations
Mayuresh M. Abhyankar
Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia
Barbara J. Mann
Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia
Jeffrey M. Sturek
Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Virginia
Savannah Brovero
Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia
G. Brett Moreau
Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia
Anjali Sengar
Departments of Molecular Physiology and Biomedical Engineering, University of Virginia
Crystal M. Richardson
INDOOR Biotechnologies, Inc.
Sayeh Agah
INDOOR Biotechnologies, Inc.
Anna Pomés
INDOOR Biotechnologies, Inc.
Peter M. Kasson
Departments of Molecular Physiology and Biomedical Engineering, University of Virginia
Mark A. Tomai
3M Corporate Research and Materials Lab
Christopher B. Fox
Infectious Disease Research Institute
William A. Petri
Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia
DOI
https://doi.org/10.1038/s41541-021-00399-0
Journal volume & issue
Vol. 6,
no. 1
pp.
1
– 6
Abstract
Read online
Abstract We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine.
Published in npj Vaccines
ISSN
2059-0105 (Online)
Publisher
Nature Portfolio
Country of publisher
United Kingdom
LCC subjects
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website
https://www.nature.com/npjvaccines/
About the journal
WeChat QR code
Close